orticumab

Orticumab is a fully human IgG1 monoclonal antibody that specifically targets oxidized low-density lipoprotein (oxLDL), a key driver of arterial inflammation and destabilization of atherosclerotic plaques. By binding to an aldehyde-modified epitope (amino acids 661–680) on apolipoprotein B-100 within oxLDL, orticumab sequesters and promotes clearance of oxLDL from inflamed coronary arteries. This targeted action reduces cytotoxic and pro-inflammatory effects associated with oxLDL, inhibits macrophage activation in atherosclerotic plaques via the inhibitory FcγII receptor, and may decrease plaque burden while preventing major cardiovascular events such as acute coronary syndrome and heart attack. Orticumab is being developed primarily for the treatment of coronary artery disease with high residual inflammatory risk—especially in patients with psoriasis who are at increased risk for adverse cardiac events[1][3][4][5].

Other names

Anti-oxLDL